Home › Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP
 

Keywords :   


Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP

2014-07-30 10:19:09| drugdiscoveryonline Home Page

Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all

Tags: data study reports drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Hurricane Leslie Graphics
06.10Hurricane Kirk Graphics
06.10Hurricane Leslie Forecast Discussion Number 15
06.10Hurricane Leslie Wind Speed Probabilities Number 15
06.10Hurricane Leslie Public Advisory Number 15
06.10Summary for Hurricane Leslie (AT3/AL132024)
06.10Hurricane Leslie Forecast Advisory Number 15
06.10Hurricane Kirk Forecast Discussion Number 27
More »